Overview

Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:
0

Participant gender:
All

Summary

Registration study

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Caspofungin
Echinocandins

Criteria

Inclusion Criteria:

- Patient has had an absolute neutrophil count < 500/mm3 for at least 96 hours (the
patient must not be expected to recover from neutropenia in the next 48 hours), and
has received at least 96 hours of parenteral broad spectrum systemic antibacterial
therapy preceding study entry, and patient has fever >38.0 Degrees Centigrade within
the last 24 hours prior to study entry

- Appropriate antibiotics are those that provide broad spectrum gram-positive and
gram-negative coverage

Exclusion Criteria:

- Patient has an inadequately managed bacterial infection at the time of enrollment